Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
PF4 Antibody Persistence and Long-term Pathogenicity in VITT
Anand Padmanabhan/LinkedIn
Nov 29, 2025, 16:38

PF4 Antibody Persistence and Long-term Pathogenicity in VITT

Anand Padmanabhan, Professor and Consultant at Mayo Clinic, shared on LinkedIn:

”Congrats to Adam Kanack, Emily Mauch, Guillaume Roberge, and coauthors related to their study on long-term persistence and pathogenicity of VITT antibodies.

Key points:
– Despite clonal restriction of Anti-PF4 abs in VITT, unlike MGTS, these monoclonal spikes are not seen when the entire IgG repertoire is examined. You unmask anti-PF4 clonal restriction only when you isolate the anti-PF4 antibodies
– In some cases, VITT abs can comprise kappa light chains (dogma to date is that it can only be lambda)
– As shown in a case in our report, thrombocytopenia can persist for more than 4 years.”

Read the full article here.

Title: Platelet Factor 4 Antibody Persistence and Long-term Pathogenicity in Vaccine-induced Immune Thrombotic Thrombocytopenia

Authors: Adam Kanack, Emily Mauch, Guillaume Roberge, Noah Splinter, Krishna Gundabolu, Geoffrey D. Wool, Gemlyn George, Mouhamed Yazan Abou-Ismail, Kristi J. Smock, David L. Green, Jonathan Coker, Mindy C. Kohlhagen, David L. Murray, Anand Padmanabhan

 

Keep up with Hemostasis Today.

Adam Kanack Anand Padmanabhan Anti PF4 Antibodies Anti-PF4/H Antibodies David L. Green David L. Murray Emily Mauch Gemlyn George Geoffrey D. Wool Guillaume Roberge Health Hematology Hemostasis Hemostasis Today Jonathan Coker Krishna Gundabolu Kristi J Smock Mayo Clinic Medicine Mindy C. Kohlhagen Mouhamed Yazan Abou-Ismail Noah Splinter PF4 Platelet Factor 4 Platelet Factor 4 Antibody thrombocytopenia thrombosis TTP Vaccine-induced Immune Thrombotic Thrombocytopenia VITT
NewsFeed